<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel><title>FDA orders new warning labels on Ozempic, Wegovy over rare risk of permanent vision loss — Live Feed</title><link>https://www.live-feeds.com/feed/fda-orders-new-warning-labels-on-ozempic-wegovy-over-rare-risk-of-permanent-vision-loss</link><atom:link xmlns:atom="http://www.w3.org/2005/Atom" href="https://www.live-feeds.com/feed/fda-orders-new-warning-labels-on-ozempic-wegovy-over-rare-risk-of-permanent-vision-loss/rss.xml" rel="self" type="application/rss+xml"/><description>Continuously updated, source-cited coverage.</description>
<item><title>FDA Orders Vision Loss Warnings for GLP-1 Drugs</title><link>https://www.live-feeds.com/feed/fda-orders-new-warning-labels-on-ozempic-wegovy-over-rare-risk-of-permanent-vision-loss</link><guid isPermaLink="false">https://www.live-feeds.com/feed/fda-orders-new-warning-labels-on-ozempic-wegovy-over-rare-risk-of-permanent-vision-loss#u203895</guid><pubDate>Mon, 16 Nov 2026 11:31:10 +0000</pubDate><description>Federal regulators have mandated new warning labels regarding a rare risk of permanent vision loss and sudden blindness across the entire class of GLP-1 receptor agonist medications. The safety action applies to widely used diabetes and weight-loss treatments including Ozempic, Wegovy, Mounjaro, and Zepbound. The updated product labeling highlights the potential danger of developing non-arteritic anterior ischemic optic neuropathy, a serious eye condition. Users have previously filed lawsuits alleging they developed the vision-damaging condition after taking these popular therapies.Why it matt</description></item>
</channel></rss>